Grade 1 Endometrial Cancer at 29: Progestin Therapy Against the Clock She's Watching
Fertility-sparing progestin therapy can work in early, low-grade endometrial cancer — roughly half the time, over months, with a real relapse rate afterward, and against an MRI that can't fully rule out the deeper invasion it's designed to exclude. Hysterectomy is curative and immediate. The disagreement is about how much oncologic certainty a 29-year-old should be asked to trade for a chance at carrying a pregnancy herself.
Jenna T. is engaged, has set no wedding date because she wanted to know what she was dealing with first, and became a first-time aunt last month when her identical twin sister had her second baby — a coincidence of timing that has made her own diagnosis, six weeks later, harder to sit with than she expected. Abnormal uterine bleeding at 29 led to an endometrial biopsy that returned grade 1 endometrioid adenocarcinoma, and pelvic MRI showed a thickened endometrium with no definite myometrial invasion, consistent with disease confined to the endometrial lining. Her BMI sits in the obese range, a common enough backdrop for this exact histology and age group, driven by chronic unopposed estrogen exposure rather than any inherited risk.
Standard treatment for endometrial cancer at any grade is hysterectomy, which is curative and ends the disease question the same day it's performed — and also ends any possibility of Jenna carrying a pregnancy herself. Fertility-sparing progestin therapy, using high-dose oral progestins or a levonorgestrel intrauterine device, offers an alternative that a 2012 systematic review and meta-analysis by Gallos and colleagues puts honestly in context rather than optimistically: 76.2% of early-stage carcinomas achieved regression across the pooled studies, response confirmed only by repeat endometrial sampling rather than imaging — but 40.6% of those who responded later relapsed, and the pooled live birth rate was 28%. Read together, those three numbers describe a strategy that usually works once and often does not hold, which is a different offer than a response rate alone makes it sound. The complication MRI itself introduces is that it is not fully sensitive to the depth of invasion it's being asked to rule out — a small number of tumors read as endometrium-confined on imaging turn out, on eventual surgical pathology, to have invaded the myometrium after all, meaning a course of progestin therapy in a patient who was never truly Stage IA to begin with is a real, if uncommon, risk baked into every fertility-sparing attempt at this stage of the workup. The feMME trial paired progestin therapy with metformin and structured weight loss on the theory that reducing the unopposed-estrogen drivers behind this exact histology improves response odds beyond the hormone alone; Jenna agreed to add metformin to her own regimen on that basis, understanding it as a modest adjunct rather than a guaranteed improvement.
How long a trial is a trial
I'd recommend hysterectomy. This is curable today, and Gallos's pooled data is two numbers, not one: 76.2% regress, and 40.6% of those who regress relapse afterward. MRI also isn't fully sensitive for occult myometrial invasion, which means a small number of patients attempting fertility preservation are treating a cancer stage they don't actually have.
I hear the oncologic argument, and I'm not disputing the numbers — but a response rate above half, in appropriately selected grade 1, non-invasive disease, is a real option, not a false hope. Jenna has been clear and consistent about wanting to carry a pregnancy herself. I don't think we get to make that choice unavailable to her because the alternative is more certain.
"Not fully sensitive" doesn't mean MRI is unreliable here — it's the standard tool for exactly this staging question, and treating its imperfection as disqualifying would rule out fertility preservation for essentially every patient who might otherwise be a reasonable candidate.
I don't think either of you is actually wrong — I think the real problem is offering this as an open-ended trial rather than a structured one. Repeat endometrial biopsy at a fixed interval, a pre-agreed response threshold, and an automatic conversion to hysterectomy if that threshold isn't met. That gives Jenna the real chance the endocrinologist is describing, without drifting past the point where the oncologist's safety concern stops being manageable.
Agreed: levonorgestrel IUD placed as fertility-sparing therapy, with endometrial biopsy scheduled at 3 and 6 months and hysterectomy pre-agreed as the automatic next step if the 6-month sample does not show response.
Fully agreed on the structure, though the gynecologic oncologist's underlying oncologic-safety concern wasn't erased by it — the team's compromise converted a disagreement about whether to offer fertility preservation into an agreement about how tightly to bound it, which both other voices accepted as addressing their actual concerns.